Glenmark, US arm settle antitrust, consumer cases against 2 cholesterol drugs
This story was originally published at 16:51 IST on 14 November 2025
Register to read our real-time news.Informist, Friday, Nov. 14, 2025
NEW DELHI – Glenmark Pharmaceuticals Ltd. and its subsidiary Glenmark Pharmaceuticals Inc., USA have settled antitrust and consumer protection cases against them on generic Zetia and Vytorin--the drugs for the treatment of cholesterol, the Indian company said in an exchange filing.
Glenmark Pharmaceuticals Ltd. and its arm said that they have now settled with United Healthcare Services, Inc. for $11 million, which were payable in two instalments. The settlement makes clear that Glenmark Pharmaceuticals Ltd. and its arm denies each and every one of the allegations against them and the settlement was not on the basis of companies having conceded or admitted any liability or illegality, said the companies.
The lawsuits against the companies had alleged that in 2010, Glenmark entered into an anticompetitive agreement to settle patent infringement litigation involving a patent related to ezetimibe, which was the active ingredient in Zetia, with Schering Corp. and MSP Singapore Co. LLC. The petitions against Glenmark Pharmaceuticals Ltd. and its arm were divided into four groups. In 2023, Glenmark Pharmaceuticals Ltd. and its arm had settled with three groups. The fourth group of four parties had opted out of the settlement.
In February, Glenmark Pharmaceuticals Ltd. and its arm already settled the cases with three parties of the fourth group and only one party United Healthcare Services was remaining. Friday, United Healthcare Services said that they had settled with the fourth party and the litigation was fully resolved.
Friday, shares of Glenmark Pharmaceuticals ended 0.8% higher at INR 1,895.60 on the National Stock Exchange. End
Reported by Surya Tripathi
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
